|Bid||13.27 x 800|
|Ask||14.41 x 800|
|Day's Range||13.94 - 14.08|
|52 Week Range||12.68 - 22.38|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Codexis, Inc. (CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (300363.SZ) fermentation pilot laboratory located in Porton’s Changshou site, achieving another important milestone in the strategic partnership between Porton and Codexis in the field of biocatalysis technology. In 2018, in order to further expand the value adding application of biocatalysis in pharmaceutical processes, Porton and Codexis announced their strategic partnership, and Porton established licensed biocatalysis capabilities at its Shanghai R&D center.
Codexis, Inc. (CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical development and early clinical studies. The SCA, signed in 2017, was an agreement to co-discover new enzyme therapy candidates for Nestlé Health Science’s nutritional therapies portfolio.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
Codexis, Inc. (CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4TM DNA ligase high-performance molecular diagnostic enzyme. This enzyme was developed using Codexis’ proprietary CodeEvolver® protein engineering platform and is expected to be incorporated into Roche’s next generation sequencing (NGS) library preparation kits and other sequencing products.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Codexis, Inc. (CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the prestigious peer-reviewed journal Science, detailing the development of a novel, highly efficient enzymatic cascade for the production of Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The publication (https://science.sciencemag.org/content/366/6470/1255) describes the optimization, using Codexis’ proprietary CodeEvolver® protein engineering platform, of five enzymes for the synchronized synthesis of a complex pharmaceutical candidate in very few steps, starting from simple raw materials. Merck and Codexis collaborated on the engineering of the enzymes to enable the efficient synthesis of the Active Pharmaceutical Ingredient (API).
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Codexis (CDXS) delivered earnings and revenue surprises of 166.67% and 32.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver® licensing revenues Eleven customers each contributed at least a quarter.
REDWOOD CITY, Calif., Nov. 05, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in four upcoming.
REDWOOD CITY, Calif., Oct. 29, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results.
How do we determine whether Codexis, Inc. (NASDAQ:CDXS) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
Codexis, Inc. (CDXS), a leading protein engineering company, assembled approximately 150 top scientists in protein engineering to discuss recent progress and future direction in a forum held last week in Palo Alto, Calif. Speakers highlighted recent successes in enzymatic manufacturing, biologics discovery, and agricultural and diagnostic applications, as well as technical progress in library generation, high-throughput screening, and bioinformatics. The keynote address by Nobel Laureate Dr. Frances H. Arnold illuminated the audience on the history of the field and highlighted the promise of protein engineering technology.
REDWOOD CITY, Calif., Sept. 26, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor.
President and CEO of Codexis Inc (30-Year Financial, Insider Trades) John J Nicols (insider trades) bought 10,000 shares of CDXS on 08/20/2019 at an average price of $13.3 a share. Continue reading...